Lineage plasticity and epigenetic changes underlie prostate development and cancer evolution. A new study shows that basal and luminal prostate cells have distinct metabolic profiles, with a basal-to-luminal shift intensifying pyruvate oxidation. Metabolic changes in turn influence chromatin architecture, lineage reprogramming and treatment sensitivity.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Zong, Y. et al. Proc. Natl Acad. Sci. USA 109, E3395–E3404 (2012).
Beltran, H. et al. Nat. Med. 22, 298–305 (2016).
Bakht, M. K. et al. Nat. Cancer 4, 699–715 (2023).
Zadra, G. & Loda, M. Cold Spring Harb. Perspect. Med. 8, a030569 (2018).
Jadvar, H. J. Nucl. Med. 57, 25s–29s (2016).
Bakht, M. K. et al. J. Nucl. Med. 61, 904–910 (2020).
Buteau, J. P. et al. Lancet Oncol. 23, 1389–1397 (2022).
Butler, L. M. et al. Cancer Res. 81, 4981–4993 (2021).
Mishra, R. et al. J. Clin. Invest. 128, 4472–4484 (2018).
Reina-Campos, M. et al. Cancer Cell 35, 385–400.e389 (2019).
Yang, Q. et al. Cell Metab. 24, 542–554 (2016).
Giafaglione, J. M. et al. Nat. Cell Biol. https://doi.org/10.1038/s41556-023-01274-x (2023).
Latham, T. et al. Nucleic Acids Res. 40, 4794–4803 (2012).
Lu, X. et al. Nat. Genet. 54, 670–683 (2022).
Davis, M. I., Bennett, M. J., Thomas, L. M. & Bjorkman, P. J. Proc. Natl Acad. Sci. USA 102, 5981–5986 (2005).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
H.B. has served as a consultant/advisory board member for Janssen, Astellas, Astra Zeneca, Merck, Pfizer, Foundation Medicine, Amgen, Bayer, Oncorus, LOXO, Daicchi Sankyo and Curie Therapeutics (for work unrelated to the present study). H.B.’s institution has received research funding from Janssen, AbbVie/Stemcentrx, Eli Lilly, Astellas, Millennium, Bristol Myers Squibb, Circle Pharma, Daicchi Sankyo and Novartis (for work unrelated to the present study). M.K.B. declares no competing interests.
Rights and permissions
About this article
Cite this article
Bakht, M.K., Beltran, H. Metabolically regulated lineages in prostate cancer. Nat Cell Biol 25, 1726–1728 (2023). https://doi.org/10.1038/s41556-023-01298-3
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41556-023-01298-3